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Abstract
Cancer clinical trials are important for resolving cancer health disparities for
several reasons; however, clinical trial participation among African Americans
is significantly lower than Caucasians. This study engaged focus groups of 82
female African American cancer survivors or cancer caregivers, including those
in better resourced, more urban areas and less resourced, more rural areas.
Informed by an integrated conceptual model, the focus groups examined per-
ceptions of cancer clinical trials and identified leverage points that future
interventions may use to improve enrollment rates. Study findings highlight
variation in community knowledge regarding cancer clinical trials, and the
importance of community education regarding clinical trials and overcoming
historical stigma associated with clinical research specifically and the health
care system more generally. Study participants commented on the centrality of
churches in their communities, and thus the promise of the church as loci of
such education. Findings also suggested the value of informed community
leaders as community information sources, including community members
who have a previous diagnosis of cancer and clinical trial experience. The
sample size and location of the focus groups may limit the generalizability of
the results. Since the women in the focus groups were either cancer survivors
or caregivers, they may have different experiences than nonparticipants who
lack the close connection with cancer. Trust in the health system and in one’s
physician was seen as important factors associated with patient willingness to
enroll in clinical trials, and participants suggested that physicians who were
compassionate and who engaged and educated their patients would build
important trust requisite for patient participation in clinical trials.
Introduction
Substantial cancer disparities exist between Caucasians
and African Americans in the United States (US). African
Americans are diagnosed with more advanced cancer,
experience higher mortality rates, and have substantially
lower 5-year survival rates than Caucasians [1]. In North
Carolina, minority women have a 49% greater breast
cancer mortality rate than Caucasian women [2]. Racial
differences can largely be attributed to barriers for African
Americans in accessing high-quality medical care and
treatment [1, 3–5].
Cancer clinical trials are important for resolving cancer
health disparities for several reasons. In the short term, they
are associated with high-quality, guideline-driven health
care. In the longer term, heterogeneity of trial participants
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is important for the development of new interventions that
are broadly effective, and not just effective in a subset of the
population [6]. Unfortunately, less than 5% of adult cancer
patients are enrolled in a cancer clinical trial sponsored by
the National Cancer Institute (NCI) [7]. Among the 5% of
adults participating in cancer clinical trials, less than 10%
are African Americans [8]. A recent study of North Carolina
enrollment rates in NCI trials found that although the state’s
enrollment rates are comparable to national enrollment
estimates, participation is lowest among African Americans.
The racial disparity between Caucasians and minorities
appears to be widening, and numerous North Carolina
counties had no minority trial enrollment whatsoever [9].
One barrier to clinical trial enrollment is related to lack
of access to the health care system [10], which often times
disproportionately affects African Americans [11]. Other
factors that have been cited as barriers include time travel-
ing to clinics and office visits, health literacy, and chal-
lenges navigating the health care system [12, 13]. Surveys
examining clinical trial enrollment barriers among African
Americans have shown mixed results. In a pilot survey
expanding African American physician perceptions about
clinical trials, 166 physician reported that low enrollment
were due to lack of patient awareness and patient mistrust
of the medical community [14]. However, another study
involving 70 African Americans revealed that the most
important reason for not participating in clinical trials was
health-related risks including side effects and interfering
with current medications. This led the authors to conclude
that African Americans were predominantly influenced by
practical issues, rather than psychosocial perceptions [15].
While recent qualitative studies have focused on clinical
trial enrollment and minorities, no studies have focused
specifically on African American women and cancer clini-
cal trial enrollment [16, 17]. The authors of this study
recently conducted focus groups with African American
prostate cancer survivors and their caregivers regarding
their perceptions of cancer clinical research [16]. Results
showed that men were often confused about the relation-
ship among clinical trials, treatment, and research, as well
as apprehension to discuss health issues with a physician
and overall mistrust in the medical system. The literature
documents that men and women have different perspec-
tives and approaches to health and health care, especially
in the African American community. Additionally, cancer
treatment and clinical trials differ substantially between
women and men. For example, the most common cancer
among African American women is breast cancer,
accounting for 30% of all female cancer cases. Breast can-
cer treatment is very advanced, with innumerous combi-
nations of therapies depending on the specific results of
very advanced genetic and cellular tests. The most com-
mon cancer among African American men is prostate can-
cer, accounting for nearly 40% of all cancer cases, which
has virtually no diagnostic tests that can inform treatment
decisions, and treatment options are profoundly few.
Therefore, to better understand why African American
women have low enrollment rates in clinical trials, focus
groups were used to elicit African American women’s
thoughts, attitudes, and beliefs regarding cancer clinical
trials. More specifically, our purpose was to determine the
perceived barriers and facilitators to participating in cancer
clinical trials. Using focus groups are advantageous because
they provide information that would have not been
obtained through surveys or interviews [29, 30]. Due to
the varying health care norms and treatment options avail-
able for African American men and women, the authors
felt it was necessary to focus only one gender, women.
Methods
Conceptual model
The study was guided by three conceptual models: the
Lay Health Advisor model, Flaskerud and Winslow’s vul-
nerable populations’ framework, and the Behavioral
Model for Vulnerable populations [18–20]. This inte-
grated model informed our understanding of the multi-
ple, interrelated characteristics that influence African
American women’s willingness to participate in cancer
clinical trials, including: (1) patient and caregiver-related
characteristics (age, race, education, health preferences,
uncertainty about research, transportation, childcare,
time, and additional costs) [21–23]; and (2) physician-
related characteristics (scheduling appointments, protocol
compliance issues, and access to and/or awareness of
trials) [24–27].
Setting
Between 2011 and 2012, eight focus groups were con-
ducted across four counties in North Carolina (two focus
groups per county): Guilford, Orange, Edgecombe, and
Nash. These four counties were sampled from two regions,
one in Central North Carolina and the other in Eastern
North Carolina. These two regions were selected for this
study to help assure diverse representation, as they are dis-
tinct from each other, and have different social and eco-
nomic factors associated with them. Guilford and Orange
counties, located in Central North Carolina, are compara-
tively better resourced, with two NCI Community Clinical
Oncology Program Network (CCOP)-affiliated hospitals
and one medical school. Nash and Edgecombe, located in
Eastern North Carolina, are less resourced, with no CCOP
hospitals or medical schools in a much more rural region
of the state. From 2006 to 2010, minorities accounted for
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approximately 20% of the newly diagnosed cancer cases
Guilford and Orange County, and 70% of newly diag-
nosed cancer cases in Nash and Edgecombe County [26].
Participant recruitment and data collection
Inclusion criteria for participants were (1) 18 years or
older (2) having a diagnosis of cancer (or a caregiver for
a person with cancer), (3) not actively undergoing cancer
treatment, and (4) having cognitive functioning sufficient
to allow completion of the study. Focus group partici-
pants were recruited with the help of community contacts
affiliated with the Carolina Community Network to
Reduce Cancer Health Disparities (CCN II), a regional
cancer network funded by the NCI Center to Reduce
Cancer Health Disparities to reduce cancer disparities in
North Carolina [31, 32]. Community contacts were indi-
viduals affiliated with nonprofit organizations, health care
organizations, and faith-based organizations with previous
cancer health disparities experience working with CCN II
and the university. Community contacts used word-of-
mouth and recruitment flyers to disseminate study infor-
mation to potential focus group participants in their
regional networks. Using community contacts to deliver
study information via word-of-mouth and flyers is an
effective recruitment strategy because they have estab-
lished relationships with cancer survivors and caregivers
and are able to quickly identify potential participants that
may have an interest in the study.
Focus groups were held at community facilities (hospi-
tals, churches, and community centers) recommended by
community partners as being familiar to and conveniently
located for participants. After determination of eligibility,
participants completed a short survey regarding demo-
graphic and cancer-related questions. To test differences
between cancer survivors and cancer caregivers, as well as
differences between regions, (central vs. eastern North Car-
olina) t-tests for continuous variables and chi-squared tests
for categorical variables were calculated. Due to the small
sample size, P < 0.10 was considered statistically signifi-
cant. Each focus group lasted approximately 90 min, and
was conducted in collaboration with an independent
research company. One African American female staff
member from this company moderated all focus groups.
Focus group discussions were digitally recorded and partic-
ipants provided verbal consent to participate. Participants
were compensated with a $60 gift card.
Moderator guide and data analysis
The conceptual models directly informed the development
of the focus group moderator guide. Focus group ques-
tions elicited discussions about perceptions of cancer clini-
cal trial participation, practical barriers to participation,
experience with clinical trials, medical decision making,
and treatment preferences. To be more specific to the con-
text of women’s health, family roles, and female-specific
cancers, the moderator guide and codebook were adapted
from our previous qualitative study with African Ameri-
can men [33]. Focus groups were transcribed verbatim
and qualitatively analyzed using the software program
Atlas.ti 6.0. Two members of the research team indepen-
dently coded eight transcripts, adding new codes based
on themes that emerged during the coding process, and
reconciling codes upon completion of independent cod-
ing. Code summaries and memos for each focus group
were written to reflect major themes and perceptions. The
research team analyzed the final themes and perceptions
within each focus group and between each focus groups.
To determine significant differences between the focus
groups, members of the research team calculated and
compared code frequencies. Researchers also assessed
baseline levels of participants’ knowledge and understand-
ing of cancer research terminology by tracking the phrases
used by participants to describe terminology. Two com-
munity collaborators affiliated with CCN II also indepen-
dently reviewed and provided thoughtful interpretation of
findings and their perceptions regarding implications.
Results
A total of 90 participants across four counties were
recruited for eight focus groups. Eight participants did
not show up for the focus groups; an 8.9% no-show rate.
The final study sample included 82 African American
women. Ages ranged from 21 to 85, with an average age
of 57 (see Table 1).
Fifty-two percent of the participants were cancer caregiv-
ers, 45% were survivors, and 2% were both. Based on t-
tests, survivors were more likely to be older than caregivers,
60.7 years versus 55.6 years, respectively (P < 0.05). Chi-
squared tests showed that 64% of survivors were either
retired or not working, compared to 51.1% of caregivers
being retired or not working, however, this was not statisti-
cally significant (P = 0.38). Additionally, survivors had
slightly lower educational achievements than caregivers,
41.0% had a high school degree or less compared to 15.6%
(P < 0.10). The majority of the survivors had breast cancer
(59%); ended treatment more than 6 months prior to the
focus group (79%); did not participate in a cancer clinical
trial (87%); and did not have their doctor talk to them
about participating in a cancer clinical trial (67%) (see
Table 2). In terms of geographic regions, participants living
in Eastern regions were more likely to work or be retired
(P < 0.05) and have higher incomes (P < 0.05) than
participants living in Central regions. Additionally,
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participants living in Eastern regions were more likely to
have some college education, but participants living in
Central regions were more likely to be college graduates
(P < 0.10).
During data analysis, we found that themes followed a
continuum of beliefs and perceptions that began with
more conceptual, vague ideas, and spanned to more con-
crete and specific issues. The conceptual ideas were
grounded in impersonal examples often based on histori-
cal/cultural contexts, while the concrete issues were more
personal, practical examples based on contemporary con-
texts and experiences. We identified four dominant themes
across all focus groups: knowledge and understanding of
cancer research terminology, distrust in US medical sys-
tem, the importance of physician trust, and importance of
faith in decision-making process (see Table 3). These
dominant themes provide insight into reasons for nonen-
rollment and may serve as leverage points for future efforts
to improve African American women’s participation in
cancer clinical trials. In general, caregivers and survivors’
responses to focus group questions did not differ widely.
Knowledge and understanding of cancer
research terminology
Literature suggests that cancer research terminology may
be an issue when communicating with patients. Therefore,
at the beginning of each focus group to gauge partici-
pants’ understanding of and preferences for these terms,
the moderator introduced various cancer research terms
that are commonly used interchangeably. The moderator
asked participants to describe in their own words defini-
tions for “clinical research,” “medical research,” “research
study,” “comparative research,” and “comparative exami-
nation,” and decide by consensus which they preferred to
use during the rest of the focus group. Five of the eight
focus groups preferred the term “medical research.” Par-
ticipants’ knowledge, understanding, and preferences for












Employment status 0.38 0.027**
Full time 21 0.26
Part time 14 0.17
Retired 28 0.34
Do not work 19 0.23
Education 0.71* 0.098*
Some high school 2 0.02
High school 21 0.26
Some college 38 0.46
College 21 0.26
Household income 0.73 0.014**
Less than $10,000 11 0.13
$10,000–$19,999 13 0.16
$20,000–$39,999 24 0.29
$40,000 or more 22 0.27
Did not answer 11 0.13






Regular source of health care 0.093* 0.68
Yes 79 0.96
No 3 0.04
1Percentages may not sum to 100 due to rounding.
*P < 0.10, **P < 0.05.
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medical terms varied between the suburban/urban areas
(Guilford and Orange county) compared to the rural
areas (Nash and Edgecombe county).
In general, the Guilford and Orange county focus groups
were knowledgeable about cancer research. Participants
thought that comparing two different treatments was
beneficial, such as the standard of care verses a treatment
that is believed to be better. They felt that random assign-
ment to the different treatment groups was fair and not
unethical. As exemplified by one woman, “You’ve already
been told up front that there’s a chance. You’ve already
been informed ahead of time that you may or may not
receive the new one or the old one, so . . . You can’t be
upset about it.” Some participants felt that the “fairness” of
receiving the old or new treatment should depend on an
individual’s case (e.g., cancer aggressiveness). Some felt that
random assignment was seen as taking one’s autonomy and
ability to make their own decision about cancer treatment.
Some women preferred receiving the old treatment versus
the experimental or “new” treatment in a clinical trial
because they thought that the old treatment was superior
to the new. The majority of participants were not surprised
that few cancer clinical trials use placebos. Everyone agreed
that they did not like the idea of clinical trial that involved
placebo and felt it was “deceptive.” Cancer treatment was
discussed as being more certain than cancer research.
Compared to the Guilford and Orange focus groups,
the Nash and Edgecombe focus groups were generally less
knowledgeable regarding cancer research and terminology.
Among group differences between the regions, the term
“clinical trial” brought up more negative references such
as “experimentation,” “guinea pig,” “trial and error”, and
“last resort.” Some women felt that one benefit of partici-
pating in a clinical trial would be the access to a support
group, which would not be available if they were receiv-
ing medical care that was not part of a trial. Using the










Non Hodgkin’s 2 0.05
Leg cancer 1 0.03
Did not answer 1 0.03
Treatment ended
More than 6 months 31 0.79
Less than 6 months 7 0.18
Did not answer 1 0.03
Have you ever participated in a cancer clinical trial?
Yes 5 0.13
No 34 0.87




Not sure 1 0.03




1Percentages may not sum to 100 due to of rounding.






of cancer research terminology
“I think the research comes first and then the
treatment because the research is gonna help
you with the treatment.”
70
Importance of faith in
decision-making process
“You have to have a holistic approach doctor. . .not
only do they deal with the cancer; they deal with
the spirituality. They believe in God, they believe in
you being healed.”
35
Distrust in medical system “I’m not from the South. You read so much on how
they just played around with the black women, just
gave them anything. Some of them sterile, some of
them can’t have children, so that trust issue is a big issue.”
25
Importance of physician trust “I would [participate in a clinical trial] if my doctor
recommended and I trust him, I would participate because
I trust his medical advice.”
21
1Total references were calculated based on the number of times participants made statements that were coded as the barriers.
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term “medical research” elicited responses such as “find-
ing a cure” and “thorough exam.” As one woman
commented, “the more research, the more possibilities
there are to finding a cure. . ..” In these groups, there was
a general lack of knowledge about the concept of random
assignment and the need for comparing two different
treatments. After the moderator explained random assign-
ment to participants, they expressed concern about not
knowing which treatment they would receive, but thought
the idea of random assignment was fair.
Distrust in medical system
There remains widespread distrust and hesitation among
African Americans with respect to medical research and
trials. As one woman commented, “With medical research
and being African Americans I know that we were used a
long time ago for that, and that’s why I think we’re so
afraid of it now because they used us in the past and we
don’t trust anyone.” Across all focus groups, when asked
about clinical trials, medical research, and research stud-
ies, multiple women expressed their concerns about
experimentation and referenced the Tuskegee Experiment.
When asked what information participants would need to
know before deciding whether to participate in cancer
medical research, the following conversation arose:
Participant: As a black woman, I need to know I’m not
being used as a guinea pig or the financial
aspects sometimes comes into play with my
race in our all-black communities.
Moderator: How would you know that you’re not being
used as a guinea pig?
Participant: Bringing us together as races, not separating
us or on applications to sign up that my
ethnic background is not asked for.
Moderator: So if your ethnic background is asked for,
what I think I hear you saying is that you
have this inkling in your mind that they’re
using you as a guinea pig?
Participant: Yes.
When asked if they would feel more comfortable par-
ticipating in a clinical trial knowing that all cancer treat-
ments underwent clinical trials, one woman said, “It is
[important] because we as a race are automatically stand-
offish and so afraid from past things. We all know about
the Tuskegee . . . and we just don’t feel comfortable par-
ticipating in things, and it’s for lack of knowledge.”
The importance of good provider communication and
being informed was highlighted in all focus groups as rele-
vant to both the health care and clinical research context.
For example, one woman whose husband participated in a
clinical trial had their oncologist discuss the entire process
with them and offer in-depth consultation. Because of the
oncologist’s willingness to take time and discuss the trial,
the woman said, “. . .that’s why I say research is good and
everything is so different now. Now, they have chemo
class. You actually go to class now before you start your
treatment and when you get there, there’s a nurse and she
knows all about you, she has all your papers there. . .And
they go over everything, and that just makes it so much
easier. They give you so much more information now.” In
sum, across all focus groups, women talked about the
importance of trusting their physicians and how this could
affect their willingness to participate in clinical trials.
Overall, women who participated in a clinical trial or had
family members participate were more likely to be more
trusting of the medical system than women who had no
experience with cancer clinical trials.
Importance of physician trust
Trusting a physician was associated with having an estab-
lished, existing relationship, and having a physician that
was caring and compassionate. When asked how partici-
pants would feel if their physician were to discuss a cancer
research study as a form of cancer treatment, one woman
captured the perspectives of several participants when she
responded, “It shows that he has some compassion. He’s
giving you all these options and you make a decision from
the options that you have been given. Some doctors are so
cut-and-dry. . . if he sits down and he goes through all of
this, I would feel more comfortable and I would more likely
stick with him and go to whoever he refer me to.”
Physician compensation was generally a problem for the
majority of focus groups and was often tied to trusting the
physician. Most participants felt that if the physician was
receiving compensation for offering clinical trials, then it
would decrease their willingness to participate. When asked
how physician compensation would affect their willingness
to participate, one woman responded, “If he’s being com-
pensated then he might not even care about me.” This
being said, the Guilford and Orange county focus groups
tended to not see compensation as unethical as long as the
physician was forthcoming about it. “They get paid anyway
. . . If they’re going to come up with a cure, I’m for it.” One
woman saw compensation as positively affecting her will-
ingness to participate, “I think that the doctor, if he’s going
to get that check, he’s going be diligent in making sure that
he does everything that he needs to do.”
Importance of faith in the decision-making
process
One theme that transcended focus group locations was the
importance of faith in the cancer care decision-making
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process. Across all groups, multiple references about the
intersection between physicians and faith were brought
up. As one cancer survivor commented about her diagno-
sis, “I just left it in my doctor’s hands and in God’s
hands.” Another woman told a story about her physician
praying with her and how she believed it helped her health
outcome. One caregiver talked about how she would pray
to God to “instill everything in that doctor” to provide
good care. Other women discussed the importance of hav-
ing a spiritual physician.
The importance of faith also came up in regards to
cancer treatment and cancer clinical trials. As character-
ized by one survivor whose cancer had just returned,
“What do I have to lose, after I pray and He makes that
decision? I’m at the point in my life now where I would
probably say ‘bring it on.’” In contrast to the cancer sur-
vivor’s willingness to participate in a clinical trial, a survi-
vor responded, “I have a higher power, so I consider
myself healed. With me, I would never participate in a
clinical trial.”
Further reflecting on the centrality of faith within the
context of clinical trial participation among African Ameri-
can women, all of the focus group participants agreed that
posting information at churches would be a good avenue
for informing people about participating in clinical studies,
other than the doctor’s office. Women suggested posting
flyers on church bulletins, placing inserts in programs,
sending emails through church listservs, and having speak-
ers talk to the congregation. One woman talked about the
importance of having study information at church: “They
should reach out and come. I mean, 80 percent of us as a
group, as a culture, you could reach us at church.”
Discussion
The purpose of this study was to examine African Ameri-
can women’s thoughts, attitudes, and beliefs regarding
cancer clinical trials, including perceived barriers and
facilitators to participation. In this study, many themes
and issues arose that are consistent with other studies
[14, 15, 31–33]. However, the important issue about this
study’s findings is that lack of knowledge, distrust in
medical system, trust in physicians, and the importance
of faith are still very prominent themes in African Ameri-
can women’s lives today. This leads the authors to con-
clude that much is still required to be done when
addressing the health disparities between African Ameri-
cans and Whites. Several of the focus groups offered rec-
ommendations and strategies to address this gap.
While several studies highlight the importance of
addressing tangible barriers [12, 14, 15], such as cost,
health insurance, transportation, and child care, in clinical
trial participation, participants in this study felt these
barriers were not prominent themes. Some participants
mentioned cost as a barrier to participation, in terms of
health insurance and transportation, but many women
said they would do “whatever it takes” to get the best
care to survive. One woman said that cost and transpor-
tation would not be a barrier to participation because
“You just want to get better. You want to live.”
Across the eight focus groups, the level of knowledge
and understanding with respect to cancer medical
research varied. The more rural focus groups were gener-
ally less knowledgeable than the urban focus groups
regarding cancer research and terminology. Additionally,
educational opportunities for participants in their physi-
cian’s office also differed depending on the physician,
clinic, or hospital. While some patients had the opportu-
nity to discuss clinical trial information one-on-one with
a nurse educator, others were handed a brochure and
asked to call if they had questions. The fact that partici-
pants chose different terminology in focus groups to dis-
cuss cancer clinical trials is evidence that information
being described to them lacks consistency. One strategy
that could potentially be used to address this inconsis-
tency is through patient navigators. Patient navigators are
individuals who advocate on behalf of the patient, and
assist them with making informed choices by addressing
any confusion or misperceptions about clinical trial logis-
tics [17]. In a recent study examining the effectiveness of
using patient navigators among Chinese patients with
breast and gynecologic cancer, researchers found that nav-
igators improved patient’s knowledge of cancer clinical
trials and trial participation [37]. Our study suggests that
more education and one-on-one time with potential can-
cer clinical trial participants could increase enrollment.
Due to differences across geographic settings, researchers
could consider offering more education and resources to
women in rural areas than urban areas.
In terms of overcoming stigmas and historically
founded suspicions of the US medical system with respect
to research and clinical trials, many participants cited the
importance of education, physician compassion, and
communication [38, 39]. Physicians are the first point of
contact for referring patients to cancer clinical trials, and
it is important for patients that their physicians sanction
that referral. A majority of the focus group participants
expressed a desire for their physicians to be compassion-
ate and considerate, to be transparent with regard to their
remuneration, and to help them understand the informa-
tion being discussed. This finding is consistent with a
similar study conducted by the authors with African
American men in North Carolina in which physician trust
was crucial in considering cancer clinical trial participa-
tion [16]. One theme among the men that was not
present in women was the role of gender and social
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norms discussing health information and visiting the doc-
tor. This not only highlights the importance physician
trust, but the importance of cultural and social sensitivity
when treating gender-specific minority patients [40].
Based on the male/female differences in norms regarding
health and health care as discussed in the introduction,
this study’s results supports the authors’ decision to dif-
ferentiate the focus groups by gender.
One strategy suggested by participants for educating
African Americans about clinical trials is through the
church. Focus group participants all indicated the central-
ity of the church in their community and advocated for
its use in health education. Church-based interventions
have long been recognized as effective methods for
improving general health behaviors among African Amer-
icans [17, 41–43]. While the concept of church and faith
did not arise in the African American men’s focus groups,
based on this study’s finding, we believe that the church
can be effective in communicating information about
cancer clinical trials to women. This study also suggests
that other opportunities to educate African American
women about cancer clinical trials are through engaging
with community leaders, support groups, and cancer sur-
vivors. Women who have participated in clinical trials
may also be an appropriate avenue for communicating
information to potential participants, as they can offer a
personal perspective that may reach other women more
effectively. A recent study tested the effectiveness of a
15-min, culturally targeted video involving unscripted
narratives of African American patients discussing their
attitudes and experiences with clinical trials following a
cancer diagnosis. African American patients who watched
the video had a 34% increase in the likelihood of enroll-
ing in a clinical trial. The idea of using past participants
for cancer clinical trial recruitment is not widely used,
but shows promise [44].
This study has several limitations. First, the sample size
and location of the focus groups may limit the generaliz-
ability of the results. Second, since the women in the
focus groups were either cancer survivors or caregivers,
they may have different experiences than nonparticipants
who lack the close connection with cancer. Finally, char-
acteristics of people who agreed to participate in this
study may be different from those who did not agree to
participate, including that nonparticipants may be less
knowledgeable about cancer clinical trials. Future studies
with African Americans should be conducted to clarify
any differences among these groups, and also to validate
the perceptions of cancer clinical trials presented in this
study.
Our findings offer several strategies for increasing clinical
trial enrollment among African American women in North
Carolina, including continued community education and
interventions within the church setting. To combat long-
held historically based concerns about medical research,
the US health care system needs to ensure that minority
patients’ interactions with the health care system are posi-
tive, and promote the establishment of a trusting relation-
ship with physicians through open, honest information
about cancer clinical trials.
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